MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD)
Organization & Developments: ACADIA Pharmaceuticals
Parents
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD)
Children
*Acadia Pharmaceuticals received the FDA’s OK for pimavanserin (Nuplazid), the first drug approved to treat hallucinations and delusions associated with Parkinson’s disease, in 2016
*Biotech focused on central nervous system disorders
*Organization & Developments: ACADIA Pharmaceuticals (Archives 2016-2018)
2019: Acadia Adds Catalysts As More Readouts Approach _ seekingalpha.com
2019: Acadia declares early win on Nuplazid dementia study, stunning analysts and sending shares soaring – Endpoints News
2019: Acadia is making the best of it, but their latest PhIII Nuplazid study is a bust – Endpoints News
2019: Acadia unveils the positive PhIII it’s taking to FDA for expanding Nuplazid’s use in psychosis – Endpoints News
2019: Acadia: Making Hay While The Sun Shines seekingalpha.com
2020: Acadia Halts Work on Depression Drug After Late-Stage Trial Failure
2020: Acadia's Big Date
2020: The Play On ACADIA For Monday
2021: Acadia: Surprise, Surprise
2021: Acadia's Big Reveal
2022: Acadia Pharmaceuticals: I Remain Cautiously Bullish After Q3 Updates_ seekingalpha.com
2022: Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah_seekingalpha.com
2023: Acadia Pharmaceuticals: Better Times Ahead_ seekingalpha.com
2023: Acadia Pharmaceuticals: Difficult Market Masks Progress
2023: Acadia Pharmaceuticals: Legal Overhang On Nuplazid Removed_ seekingalpha.com
2023: Acadia's Daybue: A Small Patient Pool Making Big Waves_seekingalpha.com
2024: Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M
2024: Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
2024: ACADIA Pharmaceuticals Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Acadia Pharmaceuticals: Daybue Growth Concerns, Important Data Readout Coming
2024: Acadia Pharmaceuticals: Nuplazid Performs In Q2 While Daybue Disappoints Again
2024: Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
2024: Acadia Pharmaceuticals: Proving The Naysayers Wrong_ seekingalpha.com
2024: ACADIA Pharmaceuticals' SWOT analysis: stock outlook mixed as DAYBUE uptake lags
2024: Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
2024: Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET
2024: Acadia’s schizophrenia drug trial fails to meet primary endpoint_clinicaltrialsarena
2024: Evaluating Acadia's Market Position Following Pimavanserin's Clinical Setback
2024: Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families_ seekingalpha.com
2025: Acadia Pharmaceuticals Ends FY2024 On Solid Footing
2025: ACADIA Pharmaceuticals: Advancing On Several Fronts
2025: Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview
2025: Acadia Pharmaceuticals: Good Progress Means I'm Reversing My 'Sell' Call To 'Buy'
Jumps
*Key People: ACADIA Pharmaceuticals
Finance & Acquisitions: ACADIA Pharmaceuticals